At a glance
ClinicalIndex Comparison RecordN/ACompleted· 41 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment naïve Patients Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets (Viekirax®/Exviera®; 3D Regimen): The HEMATITE Study
In Brief
An observational study for Chronic Hepatitis C Virus (HCV). Completed, enrolled 41 participants across 5 sites.
Detailed Summary
This is an observational, prospective, open-label, single-arm, multicenter, real-life study designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (Viekirax®/Exviera®, 3D regimen) on total daytime physical activity and fatigue in participants with HCV GT1.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Virus (HCV)
CountriesSwitzerland
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMar 2017
Primary CompletionApr 2018
TodayJul 2026
First PostedDec 26, 2016
Enrollment StartMar 1, 2017
Primary CompletionApr 25, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.5 years ago